Anders Mellemgaard

TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.

TL;DR: Overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group, compared with those in theDocetaxe plus placebo group.

TL;DR: Overall, the incidence of cancer was increased by 16% in the cohort and the results were essentially unchanged by restriction to the subcohort of 8207 persons in whom obesity was the primary discharge diagnosis, and were also similar in the first year of follow-up after hospital discharge.

TL;DR: 18 susceptibility loci achieving genome-wide significance are identified, including 10 new loci linked with lung cancer overall and six loci associated with lung adenocarcinoma, highlighting the striking heterogeneity in genetic susceptibility across the histological subtypes of lung cancer.

TL;DR: A meta‐analysis of population‐based studies of breast cancer and reproductive variables in the Nordic countries confirmed that low parity and late age at first birth are significant and independent determinants of breast‐cancer risk, and suggested that several individual Nordic studies may have had too little power to detect the weak effect of age atFirst birth observed in the meta-analysis.